Agile Therapeutics, Inc.

OTCPK:AGRX Stock Report

Market Cap: US$10.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Agile Therapeutics Valuation

Is AGRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGRX?

Key metric: As AGRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGRX. This is calculated by dividing AGRX's market cap by their current revenue.
What is AGRX's PS Ratio?
PS Ratio0.5x
SalesUS$21.57m
Market CapUS$10.43m

Price to Sales Ratio vs Peers

How does AGRX's PS Ratio compare to its peers?

The above table shows the PS ratio for AGRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
TFFP TFF Pharmaceuticals
1.2xn/aUS$1.4m
LYRA Lyra Therapeutics
8.5x61.6%US$13.0m
JAGX Jaguar Health
1.1x34.8%US$11.8m
SHWZ Medicine Man Technologies
0.05x6.0%US$8.8m
AGRX Agile Therapeutics
0.5xn/aUS$10.4m

Price-To-Sales vs Peers: AGRX is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (4.9x).

Price to Sales Ratio vs Industry

How does AGRX's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.0x10.2%
AGRX Agile Therapeutics
 0.5xn/aUS$10.43m
OGN Organon
0.6x-0.06%US$4.07b
PRGO Perrigo
0.9x3.4%US$3.87b
AGRX 0.5xIndustry Avg. 3.0xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.0x23.9%
AGRX Agile Therapeutics
 0.5xn/aUS$10.43m
No more companies

Price-To-Sales vs Industry: AGRX is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is AGRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AGRX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

7D

-2.7%

1Y

71.0%